Posted by Michael Wonder on 14 Jul 2022
Revolo Biotherapeutics awarded Innovation Passport for ‘1805 in the United Kingdom for the treatment of moderate to severe rheumatoid arthritis
14 July 2022 - Revolo Biotherapeutics today announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the MHRA for its immune-resetting drug candidate, ‘1805, for the treatment of patients with moderately to severely active rheumatoid arthritis.
The Innovation Passport is the entry point into the Innovative Licensing and Access Pathway in the United Kingdom, designed to accelerate the licensing and access pathway to market for truly innovative medicines.
